Liftstream is an executive search recruitment company in the life sciences sector
Leaders on the Front Line
UK shows multi-stakeholder approach tackles diversity
The UK has been seriously tackling the issue of diversity in the senior ranks of British business. The Davies Review, led by the charismatic but challenging Lord Mervyn Davies, pushed UK boards to get 25% of women on the boards of FTSE 100 companies. This triggered concerted action on the part of the nominated companies because they would be publicly measured, and reported.
Editas Medicine Appoints John D. Mendlein to Board of Directors
Editas Medicine, a genome editing company based in Cambridge, Mass, has appointed John D. Mendlein to its board of directors. Mendlein has served as CEO of aTyr Pharma since 2011, as well as executive chairman for the company from July 2010 to January 2016.
AVROBIO Bolsters Senior Management Team
AVROBIO, a clinical-stage biotechnology company developing transformative cell and gene therapies targeting cancer and rare diseases, has made three senior appointments. Joining the firm’s leadership team are Kim Warren, Head of Operations, Chris Mason, Chief Science Officer, and Deanna Petersen, Chief Business Officer.
Five Resolutions for Nominations Committees to Improve Board Performance
The New Year brings a period of reflection, what will you change in the year ahead and how will you do it? There are some clear ways in which the effectiveness of the board can be improved by the way in which the nominations and governance committee discharge their responsibilities. Here we listed 5 resolutions for an effective nominations committee. Click the following links to read detailed articles on each recommendation.
SV Life Sciences Appoints Joshua Resnick as Partner
SV Life Sciences (SVLS), a life sciences venture capital firm with offices in Boston, London and San Francisco, has appointed Joshua Resnick as Partner. Based in Boston, Resnick joins SVLS’ biotech investment team which partners with experienced entrepreneurs and accomplished management teams.
Aegerion Names Mary Szela as CEO
Aegerion Pharmaceuticals, a biopharmaceutical company dedicated to the development and commercialisation of innovative therapies for patients with debilitating rare diseases, has appointed Mary Szela as CEO and a member of board of directors. Szela replaces interim CEO Sandford Smith who took over after the resignation of former CEO Marc Beer in July 2015. After stepping down as Interim CEO, Smith was appointed chairman of the board of directors, allowing him to continue to work closely with the management team to maintain the momentum on key company initiatives.
Clarus Ventures Strengthens Investment Team with 3 Hires
Clarus Ventures, a life sciences investment firm, has appointed Kiran Reddy and Robert DeBenedetto to Venture Partner, and Lazar Dimitrov to Associate. Based in the firm’s Cambridge, Mass. office, Reddy will focus on both new company formation and risk-sharing partnerships with pharmaceutical companies. DeBenedetto and Dimitrov will be based in Clarus’ South San Francisco, Calif. office.
Idera Pharmaceuticals Elects Maxine Gowen to Board of Directors
Idera Pharmaceuticals, a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, has appointed Maxine Gowen to its board of directors.